Table 3. Characteristics of patients in defined subgroups.

Characteristics	T1N2–3		T1N0–1		T2N2–3		T2N0–1
	IDC1	IMPC2	IDC	IMPC	IDC	IMPC	IDC	IMPC
toal	15	9	23	14	33	17	30	11
recurrence	3	6	1	0	13	1	6	1
ER 3
positive	13	7	18	14	21	14	17	9
negative	2	2	5	0	12	3	13	2
PR 4
positive	10	6	15	12	20	11	15	9
negative	5	3	8	2	13	6	15	2
Her2/neu 5
positive	1	1	2	1	1	2	3	1
negative	14	8	21	13	32	15	27	10
Grade
1	0	0	0	0	1	2	0	0
2	11	5	13	10	18	4	21	5
3	4	4	10	4	14	11	9	6
LVI 6
positive	6	6	5	7	14	13	5	2
negative	9	3	18	7	19	4	25	9
Multifocality
positive	0	5	2	3	3	3	1	0
negative	15	4	21	11	30	14	29	11
Anthracyclines
use	12	9	16	13	28	17	24	8
no use	3	0	7	1	5	0	6	3
Taxanes
use	5	5	2	2	18	12	6	3
no use	10	4	21	12	15	5	24	8
Endocrin e-therapy
use	12	7	18	14	20	17	19	11
no use	3	2	5	0	13	0	11	0
Average age(y)	52	46	52	53	48.	49	55	55
Median age(y)	55	52	47	55	50	50	55	57
Range of age(y)	29–67	26–57	34–83	31–69	28–76	37–67	32–80	38–82
> = 50 years	10	5	11	9	17	9	19	6
<50years	5	4	12	5	16	8	11	5

¹ IDC: invasive ductal carcinoma not otherwise specified;

² IMPC: invasive micropapillary breast carcinoma;

³ ER: estrogen receptor status;

⁴ PR: progesterone receptor status;

⁵ HER2/neu: human epidermal growth factor receptor 2 status;

⁶ LVI: Lymphovascular invasion.